Deferiere Raphael 4

What Happened

• Raphael Deferiere, Chief Accounting Officer of Centessa Pharmaceuticals plc (CNTA), was granted a total of 53,000 equity awards on February 2, 2026. The filing shows 11,000 shares reported as a grant (RSUs) and 42,000 reported as derivative awards; the reported acquisition price for both lines is $0. These are compensation awards, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (filed the next day).
• Grants reported: 11,000 RSUs (grant) and 42,000 derivative awards; acquisition price $0 for each line.
• Post-transaction holdings: not specified in the provided filing details.
• Footnotes of note:
  • F1: Ordinary Shares may be represented by American Depositary Shares (each ADS currently equals one Ordinary Share).
  • F2: The 11,000 share grant represents Restricted Share Units (RSUs); each RSU is a contingent right to one Ordinary Share and will vest/settle in four equal annual installments beginning Feb 2, 2027.
  • F3: The 42,000 derivative awards vest monthly at 1/48th per month, with the first monthly vesting on March 2, 2026.
• Transaction code: A (award/grant). No sale or purchase reported; no immediate cash proceeds.

Context

• RSUs and derivative awards are compensation that convert to actual shares only as they vest; they do not represent an immediate purchase or sale and therefore are not a direct bullish/bearish market signal by themselves.
• The derivative line appears to follow a 4-year monthly vesting schedule (standard service-based vesting); the RSUs follow a 4-year annual cliff-style schedule starting in 2027.
• Filing was timely (reported the day after the transaction).